WE RESEARCH. WE DEVELOP. WE FIGHT.

FOR A WORLD WITHOUT TYPE 1 DIABETES.

 

© Helmholtz Zentrum München / Jörg Simanowski (Markenfotografie)

The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) was launched in 2015 and brings together several academic research institutions and hospitals in Europe. GPPAD aims to establish an international infrastructure for studies dedicated to preventing the development of type 1 diabetes.

GPPAD locations in five countries are making every effort to achieve a world without type 1 diabetes

We conduct studies in Belgium, Germany, the UK, Poland, and Sweden for the early detection of an increased genetic risk of type 1 diabetes and prevention of disease development.

Participation in our studies is free and voluntary!

 

Read more about our studies here

 

Increased risk of type 1 diabetes: Early detection

Freder1k: early detection for newborns up to 7 days old

 

More than

Infants were tested for increased risk of type 1 diabetes

New study on the prevention of type 1 diabetes autoimmunity. 

SINT1A: for newborns up to 6 weeks old with an increased risk of type 1 diabetes.

 

In total

children are taking part in our SINT1A prevention study

Prevention study for infants with an increased risk

POInT: for infants between four and seven months old

 

In total

children are taking part in our POInT prevention study

Secured By miniOrange